# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Barbara Jordan (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML030-SYN
- Date: 2026-10-26
- Fictional facility: St. Posthumous Health Center
- Fictional author: Evangeline Moss, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Eight-month review before the first full ocrelizumab dose: re-baseline brain MRI, blood counts and immunoglobulins, seasonal vaccines, mobility and work. **S**

## History of present illness

Ms. Jordan returns ten weeks after her preventive visit, with a re-baseline brain MRI this morning. She has had no new symptoms and no infection since her first doses. Her mammogram in August was normal, and her HPV test was negative. The heat sensitivity eased as the weather cooled. She finished her course of physical therapy and keeps up her home program and pool exercise; she has had no falls since the near-fall in July. She is teaching a full term and gave two public lectures this month, seated at a lectern. She gets up once a night or less. Dr. Watanabe has reviewed the MRI. Her next infusion, the first full 600 mg dose, is booked in two weeks. **S**

| Element | Detail |
|---|---|
| New symptoms | None |
| Screening | Mammogram normal; HPV negative |
| Falls | None; one near-fall in July |
| Work | Full teaching term and public lectures |
| Next infusion | 600 mg in two weeks |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever, infection or weight change |
| Respiratory | Negative | No cough |
| Gastrointestinal | Negative | No diarrhea |
| Genitourinary | Negative | No burning; nocturia once or less |
| Neurological | Negative | No new numbness, weakness or visual change |
| Psychiatric | Negative | Mood steady |

6 systems reviewed. **S**

## Current medications

- Cholecalciferol (vitamin D3) 2000 units (50 mcg) oral capsule, one capsule daily **S**
- Baclofen 10 mg oral tablet, one tablet three times a day **S**
- Mirabegron 25 mg extended-release oral tablet, one tablet daily **S**
- Ocrelizumab 300 mg intravenous infusion on day 1 and day 15, then 600 mg every 6 months, after methylprednisolone 100 mg intravenously, an antihistamine and acetaminophen, in the infusion center **S**

## Allergies

- No known allergy **S**

## Objective

BP 120/76 mmHg; pulse 72 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 83.2 kg; BMI 27.8 kg/m². All vital signs are synthetic.

White cells: 6.1 10*3/uL; Lymphocytes (absolute): 1.5 10*3/uL; Hemoglobin: 13.5 g/dL; Platelets: 255 10*3/uL; IgG: 1010 mg/dL; IgM: 72 mg/dL; Creatinine: 0.8 mg/dL; eGFR (CKD-EPI 2021): 93 mL/min/1.73 m²; ALT: 19 U/L; AST: 21 U/L. All results are synthetic.

## Change since baseline

- White cells: 6.4 10*3/uL at baseline, 6.1 10*3/uL at this visit **S**
- Lymphocytes (absolute): 1.9 10*3/uL at baseline, 1.5 10*3/uL at this visit **S**
- Hemoglobin: 13.2 g/dL at baseline, 13.5 g/dL at this visit **S**
- Platelets: 262 10*3/uL at baseline, 255 10*3/uL at this visit **S**
- IgG: 1080 mg/dL at baseline, 1010 mg/dL at this visit **S**
- IgM: 110 mg/dL at baseline, 72 mg/dL at this visit **S**
- Creatinine: 0.78 mg/dL at baseline, 0.8 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 96 mL/min/1.73 m² at baseline, 93 mL/min/1.73 m² at this visit **S**
- ALT: 18 U/L at baseline, 19 U/L at this visit **S**
- AST: 20 U/L at baseline, 21 U/L at this visit **S**

## Immunizations given today

- Influenza vaccine, inactivated, this season **S**
- COVID-19 vaccine, mRNA, this season **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 83.2 kg; blood pressure 120/76, pulse 72; temperature 36.6 °C |
| Neurological | Spastic gait with a cane; modified Ashworth 1+ in both legs; hip flexor strength 4 out of 5; EDSS 6.0; timed 25-foot walk 11.0 seconds |
| Skin | No rash or cold sores |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Active primary progressive multiple sclerosis** (G35.B1). Re-baseline brain MRI without gadolinium: no new or enlarging T2 lesions compared with the diagnostic scan. Disability stable at EDSS 6.0 with a steady timed walk. White cells 6.1, lymphocytes 1.5, hemoglobin 13.5 g/dL, platelets 255; IgG 1010 and IgM 72 mg/dL, both normal; ALT 19 and AST 21 U/L; creatinine 0.80 mg/dL. Safe to give the 600 mg dose. **S**
   - Ocrelizumab 600 mg in two weeks, with premedication.
   - Influenza and COVID-19 vaccines today, two weeks before the infusion.
   - Next brain MRI in one year; immunoglobulins and blood count before each dose.
   - Dr. Watanabe to review in six months.
2. **Spastic gait and fall risk** (R26.89). No falls since one near-fall in the July heat; physical therapy completed. **S**
   - Continue the home program, pool exercise and baclofen 10 mg three times a day.
   - Scooter assessment remains open to her.
3. **Neurogenic bladder** (N31.9). Controlled on mirabegron; blood pressure normal. **S**
   - Continue mirabegron 25 mg daily.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | New or worsening symptoms (relapse, pseudo-relapse with heat or infection) | Every visit | Completed today | No relapse in eight months |
| Examination | Disability: EDSS and timed 25-foot walk | Every visit, and at least every 6 months | Completed today | EDSS 6.0; timed 25-foot walk 11.0 seconds |
| Imaging | Brain MRI | At diagnosis with gadolinium; re-baseline 3 to 6 months after starting therapy; then yearly without routine gadolinium | Completed today | Re-baseline without gadolinium, five to six months after the first dose: no new or enlarging T2 lesions; next in one year |
| Imaging | Spinal cord MRI | At diagnosis; later only for new spinal symptoms or diagnostic doubt | Not indicated | No new spinal symptoms |
| Laboratory | Blood count with absolute lymphocytes | Before the first dose, then before each dose | Completed today | White cells 6.1, lymphocytes 1.5, hemoglobin 13.5, platelets 255 |
| Laboratory | Quantitative immunoglobulins | Before the first dose, then before each dose | Completed today | IgG 1010, IgM 72 mg/dL |
| Laboratory | Liver tests | Before the first dose, then with symptoms and before each dose | Completed today | ALT 19, AST 21 U/L; creatinine 0.80 mg/dL |
| Medication safety | Infusion reactions and infections | Each infusion, and every visit | Completed today | No infections; 600 mg dose booked in two weeks |
| Medication safety | Influenza and COVID-19 vaccines | Each season, ideally at least 2 weeks before an infusion | Completed today | Both given today |
| Medication safety | Breast cancer screening (ocrelizumab label: standard screening) | Every two years from 40 | Up to date | Mammogram normal in August |
| Examination | Spasticity (modified Ashworth) and baclofen tolerance | Every visit | Completed today | Modified Ashworth 1+ |
| Examination | Bladder: urgency, nocturia, urinary infection, and blood pressure on mirabegron | Every visit | Completed today | Nocturia once or less; blood pressure 120/76 |
| Referral | Falls, walking aids and physical therapy | Every visit | Completed today | Physical therapy course completed; no falls |
| Self-management | Fatigue and heat sensitivity | Every visit | Completed today | Heat sensitivity eased with cooler weather |
| Laboratory | 25-hydroxyvitamin D | At baseline, 8 to 12 weeks after repletion, then yearly | Up to date | 34 ng/mL four months ago; recheck at one year |
| Imaging | Bone density | Once for reduced mobility and earlier steroid courses; repeat by risk | Up to date | Normal for age at the preventive visit |
| Survey | Depression screen (PHQ-9) | At intake, then every 6 months and with any change | Due | PHQ-9 3 four months ago and PHQ-2 0 ten weeks ago; next PHQ-9 at the next review |
| Self-management | Workplace accommodation | At intake and with any change | Completed today | Accommodations working; no change needed |
| Referral | Multiple sclerosis neurology review | At diagnosis, then every 6 months on therapy | Completed today | Dr. Watanabe reviewed the MRI and results and agreed with the plan; review in six months |

## Goal progress

- Diagnosis confirmed and classified, vaccines completed at least two weeks before therapy, and a disease-modifying therapy started within ten weeks. Outcome by 2026-06-29: Primary progressive disease confirmed at two weeks; vaccines finished at five weeks; ocrelizumab started at nine weeks. **S**
- No falls through eight months. Outcome by 2026-10-26: No falls; one near-fall in the summer heat. **S**
- 25-hydroxyvitamin D at least 30 ng/mL within four months. Outcome by 2026-06-29: 34 ng/mL at four months. **S**
- Up no more than once a night to pass urine within three months. Outcome by 2026-06-29: Once a night or less on mirabegron. **S**
- Keep her full teaching and speaking schedule with the accommodations she chooses. Outcome by 2026-10-26: Full schedule kept; accessible rooms, seating and parking in place. **S**
- No new or enlarging T2 lesions on the re-baseline MRI. Outcome by 2026-10-26: No new or enlarging T2 lesions. **S**

## Guideline basis

- Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (Rae-Grant A, et al.; PMID 29686116) (2018), American Academy of Neurology (Neurology)
- 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis (Wattjes MP, et al.; PMID 34139157) (2021), MAGNIMS, CMSC and NAIMS (Lancet Neurology)
- Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis (Farez MF, et al.; PMID 31462584) (2019), American Academy of Neurology (Neurology)
- OCREVUS (ocrelizumab) injection, prescribing information (2026), U.S. National Library of Medicine, DailyMed (Genentech label)
- Multiple sclerosis in adults: management (NG220) (2022), National Institute for Health and Care Excellence
- Accommodation and Compliance: Multiple Sclerosis (2026), Job Accommodation Network (U.S. Department of Labor)
- Introduction to the Americans with Disabilities Act (2026), U.S. Department of Justice
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force
- CMID: Clinical Monitoring Intelligence Database, osteoporosis and depression monographs (2026), Aether Forge
- Breast Cancer: Screening (2024), U.S. Preventive Services Task Force

## Follow-up

- Ocrelizumab 600 mg in two weeks. Review in three months with the PHQ-9, or the same day for new or worsening symptoms lasting more than 24 hours, fever, or a persistent infection. **S**

